C4X Discovery signs licensing deal worth more than £200m

C4X Discovery, the Manchester-based drug research firm, has signed a licensing deal which could be worth £213m.

The deal has been struck with Indivior UK.

They plan to further develop and commercialise C4XD’s Orexin-1 receptor antagonist for the treatment of addiction.

C4X3256 aims to treat addiction by targeting the “craving” process itself and, therefore, can be applied across a broad range of substance use disorders.

The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an estimated £9.26bn per annum in 2018.

Under the terms of the agreement, C4XD will receive an upfront payment of £7.12m and could secure up to £202m of potential development, regulatory and commercialisation milestones in addition to royalties.

In turn, Indivior will receive a global and exclusive licence to Orexin-1 and all other compounds in the same patent family.

C4X3256 has the potential to represent a major new method of treating addiction and related disorders, says C4X Discovery.

Dr Clive Dix, chief executive of C4X Discovery, said: “Our goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

“This agreement will allow us to accelerate the development of our portfolio to similar successful commercial arrangements and validates our business model.”

Click here to sign up to receive our new South West business news...